PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Abstract 3327: Structure and function of the L-MYC N-terminus impacts strategies to inhibit the MYC family of oncoproteins

View Full Paper
TKTristan M. G. KenneySHScott HoulistonPLPing Lin

Key Points

  • The aim is to investigate the structural and functional characteristics of L-MYC and its implications for developing broad-spectrum MYC inhibitors.
  • Assess L-MYC expression levels in primary tumor samples compared to normal tissues.
  • Analyze N-terminal region of L-MYC using NMR spectroscopy.
  • Evaluate interactions between L-MYC and known MYC-interacting proteins.
  • L-MYC expression is anti-correlated with MYC and elevated in various tumors.
  • NMR analysis shows L-MYC is largely intrinsically disordered.
  • L-MYC interacts with PNUTS but not with tumor suppressor Bin1.

Abstract

Abstract The MYC family of transforming oncogenes function as regulators of gene transcription and is composed of three members, MYC, MYCN and MYCL. As the c-MYC (MYC) protein is deregulated in 50% of human cancers, the role, regulation and structural features of MYC have been well-studied. By contrast, the L-MYC protein has been relatively understudied as historically, oncogenic deregulation was evident only in a subset of small cell lung carcinomas (SCLCs). However, with recent deep genomic analyses of primary patient samples, L-MYC has been shown to be deregulated in numerous human cancers. With this revelation it is important to understand how the L-MYC protein compares to MYC at the structural level, particularly for the development of broad-spectrum inhibitors of the MYC family. Here we first show that L-MYC expression is anti-correlated with MYC expression and is elevated in several primary patient tumor samples compared to normal, providing further evidence for L-MYC as a driver oncoprotein in primary human cancers. Next, we provide new insights into the biophysical features of an N-terminal region within the transactivation domain of L-MYC, which harbors two regions conserved amongst the MYC family: MYC box 0tbox0 (MB0) and MYC box I (MBI)tboxII. NMR spectroscopy of residues 1-80 of L-MYC confirms that, similar to MYC, it is largely intrinsically disordered and interacts with the known MYC MB0-interacting protein, PNUTS (Phosphatase 1 NUclear Targeting Subunit). On the other hand, L-MYC does not interact with the MYC MB1-interacting protein Bin1 (Bridging integrator 1), suggesting a potential mechanism by which L-MYC evades this tumor suppressor. Together, these results further substantiate the oncogenic role of L-MYC in human cancer and deeply enhance our understanding of the biophysical nature of L-MYC to better inform strategies for the development of anti-cancer therapeutics targeting the MYC family of oncoproteins. Citation Format: Tristan M. Kenney, Scott Houliston, Peter Chien-feng Lin, Nikan Movahedi, Cheryl Arrowsmith, Linda Z. Penn. Structure and function of the L-MYC N-terminus impacts strategies to inhibit the MYC family of oncoproteins abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3327.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kenney et al. (2026) studied this question.

synapsesocial.com/papers/69d1fdf7a79560c99a0a45d4https://doi.org/10.1158/1538-7445.am2026-3327
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Structure and function of the L-MYC N-terminus impacts strategies to inhibit the MYC family of oncoproteins2026
  2. 2Abstract 4761: Investigation of the role of N-MYC in lung neuroendocrine carcinoma2026
  3. 3Abstract 7072: MYC acetylated lysine residues drive oncogenic cell transformation and regulate select genetic programs for cell adhesion-independent growth and survival2024
  4. 4Abstract 3495: Characterizing the MYC-induced immunopeptidome2026
  5. 5Abstract 3055: Targeting the MKK3/MYC protein-protein interaction to overcome drug resistance in MYC-driven cancers2026